Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

Roche reported its Tecentriq drug failed to significantly improve overall survival in a late-stage bladder cancer study, raising questions about whether regulators may scale back their approval, Reuters explains. Roche won fast-track approval last May in the US for Tecentriq against bladder cancer but full approval hinged on further trials. “This puts the existing US bladder cancer approval in serious doubt,” Kepler Cheuvreux analyst David Evans wrote to investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Medicare needs to get out of the erections biz. They stopped covering ED drugs in 2003 but carved out an exception for the pumps, which in hindsight was a mistake. Most of these gizmos don’t work that well too, as Hans and Franz said on SNL, to “pump you up”.

Comments are closed.